Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

413

HTML

3539

Figures (1-3)

247

Tables (1-6)

310

Sum=4509

Aug 14, 2009 (publication date) through Feb 14, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Aug 14, 2009; 15(30): 3713-3724
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3713

Table 5 Hepatotoxicity of highly active anti-retroviral therapy drugs and guidelines for their use in patients with liver disease

Group	Drug	Dose adjustment
NRTI	Didanosine	Use cautiously
NNRTI	Delavirdine, Efavirenz, Nevirapine	Caution with hepatic impairment
PIs	Lopinavir, Nelfinavir, Ritonavir, Saquinavir	Caution with hepatic impairment
	Atazanavir	Reduce 25% of dose in patients with CTP stage B and C
	Indinavir	Reduce dose by 25% in CTP stage B and C
	Tipranavir	Avoid in patients with CTP stage B or C
	Fosamprenavir	Avoid in patients with CTP stage C
	Darunavir	Avoid in patients with CTP stage C

Citation: Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review. World J Gastroenterol 2009; 15(30): 3713-3724
URL: https://www.wjgnet.com/1007-9327/full/v15/i30/3713.htm
DOI: https://dx.doi.org/10.3748/wjg.15.3713